Quality of life and psychological distress in patients with cutaneous lymphoma

British Journal of Dermatology

Volumn 160, Issue 4, 2009, Pages 815-822

  Sampogna, F ^a   Frontani, M ^a   Baliva, G ^a   Lombardo, G A ^a   Alvetreti, G ^a   Di Pietro, C ^a   Tabolli, S ^a   Russo, G ^a   Abeni, D ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Cutaneous lymphoma; Mycosis fungoides; Quality of life; S zary syndrome

Indexed keywords

INTERFERON; RECOMBINANT INTERLEUKIN 2; RETINOID; STEROID;

ADULT; ANXIETY DISORDER; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CONTROLLED STUDY; CUTANEOUS B CELL LYMPHOMA; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTRESS SYNDROME; FATIGUE; FEMALE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PUVA; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SEXUAL BEHAVIOR; SEZARY SYNDROME; SKIN LYMPHOMA; SKIN PAIN; SKIN SENSITIVITY;

CHRONIC DISEASE; FEMALE; HEALTH STATUS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; QUALITY OF LIFE; QUESTIONNAIRES; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 62649128463     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08992.x     Document Type: Article

References (37)

1. Whittaker SJ, Marsden JR, Spittle M et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003 149 : 1095 107.
2. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 : 3768 85.
3. Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol 2005 141 : 325 30.
4. Djulbegovic B. T-cell lymphoma. In : Decision Making in Oncology. Evidence-based Management (Djulbegovic B, Sullivan DM, eds). New York : Churchill Livingstone, 1997 91 102.
5. Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 1996 20 : 7 9.
6. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996 14 : 671 9.
7. Velikova G, Brown JM, Smith AB et al. Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology. Br J Cancer 2002 86 : 51 9.
8. Ongenae K, van Geel N, De Schepper S et al. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005 152 : 1165 72.
9. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 7.
10. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004 122 : 602 7.
11. Sampogna F, Tabolli S, Soderfeldt B et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006 154 : 844 9.
12. Petticrew M, Bell R, Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. BMJ 2002 325 : 1066.
13. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003 17 : 1485 507.
14. Dummer R, Hess-Schmid M, Burg G. Cutaneous T-cell lymphomas: prognosis and quality-of-life issues. Clin Lymphoma 2000 1 (Suppl. 1 S21 5.
15. Demierre MF, Gan S, Jones J et al. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006 107 : 2504 11.
16. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001 19 : 2456 71.
17. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001 137 : 581 93.
18. ®). Clin Lymphoma 2002 2 : 222 8.
19. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001 19 : 376 88.
20. Demierre MF, Ferzli P, Miller D. Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis. Arch Dermatol 2007 143 : 659 61.
21. Abeni D, Frontani M, Sampogna F et al. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 2005 153 : 324 30.
22. Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 1997 108 : 103 7.
23. Sampogna F, Raskovic D, Guerra L et al. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol 2008 159 : 351 9.
24. Abeni D, Picardi A, Pasquini P et al. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002 204 : 43 9.
25. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 85 : 365 76.
26. Cull A, Sprangers M, Bjordal K et al. EORTC Quality of Life Group Translation Procedure. 2002. Available at: http://groups.eortc.be/qol/downloads/ 200202translation-manual.pdf (last accessed 23 October 2008).
27. Apolone G, Filiberti A, Cifani S et al. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 1998 9 : 549 57.
28. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire: the QLQ-C30 (+ 3). J Clin Oncol 1998 16 : 1188 96.
29. Picardi A, Abeni D, Pasquini P. Assessing psychological distress in patients with skin diseases: reliability, validity and factor structure of the GHQ-12. J Eur Acad Dermatol Venereol 2001 15 : 410 17.
30. Goldberg D. The Detection of Psychiatric Illness by Questionnaire. Oxford : Oxford University Press, 1972.
31. Sampogna F, Picardi A, Chren MM et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004 66 : 620 4.
32. Norusis M. SPSS for Windows: Professional and Advanced Statistics, release 9.0. Chicago : SPSS Inc., 1999.
33. Emery CF, Frid DJ, Engebretson TO et al. Gender differences in quality of life among cardiac patients. Psychosom Med 2004 66 : 190 7.
34. Sheffield D, Biles PL, Orom H et al. Race and sex differences in cutaneous pain perception. Psychosom Med 2000 62 : 517 23.
35. Sampogna F, Chren MM, Melchi CF et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006 154 : 325 31.
36. Garssen B. Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev 2004 24 : 315 38.
37. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 2005 7 : 391 5.